Fatty acid status in patients with CF-related liver disease  by Van Biervliet, S. et al.
S80 9. Gastrointestinal and Liver Disease
324 Small intestine bacterial overgrowth (SIBO) in CF patients
A. Lisowska1, P. Sobkowiak2, W. Cichy1, A. Breborowicz2, J. Walkowiak1.
11st Chair of Pediatrics, Dept. of Gastroenterology & Metabolism, University of
Medical Sciences, Poznan, Poland; 23rd Chair of Pediatrics, Dept. of Pulmonology,
Alergology & Immunology, University of Medical Sciences, Poznan, Poland
The use of azythromycin in CF patients has been suggested as a predisposing factor
for SIBO. Hydrogen breath test (BT) is commonly used as a diagnostic tool for its
detection. The aim of the present study was to assess the signiﬁcance of: (1) clinical
status for the occurrence of SIBO and (2) the measurement of methane expiration
for the diagnosis of SIBO.
Material and Methods: The study comprised 31 CF patients without previous use
of azythromycin. In all subjects glucose hydrogen/methane BT was performed. The
nutritional status (Z-scores for body weight), exocrine pancreatic secretion (fecal
elastase-1, ELISA) and lung function (FEV1) were also determined.
Results: In 12 (38.7%) CF patients abnormal BT results were found. In addition, 4
(12.9%) subjects had borderline values. In 4 (12.9%) patients methane production
was documented. Methane results created basis for the diagnosis of SIBO in 33.3%
(4 out of 12) of cases. Nutritional and clinical status was not statistically different
in patients with/without SIBO (Table).
Similarly, P. aeruginosa colonization was not different in both subgroups (66.7%
vs. 60.0%).
Conclusions: For the detection of SIBO in CF patients combined measurement
of hydrogen and methane should be applied. Excessive bacterial colonization of
small intestine does not seem to be extensively related to clinical expression of the
disease.
Supported by: MSHE grant N40605431.
Parameter Subgroup, median (mean±SEM)
With SIBO (n = 12) Without SIBO (n = 15)
Z-score for body weight −1.22 (−1.06±0.06) −0.87 (−0.99±0.19)
FEV1 (%) 73 (77±6) 88 (84±4)
Fecal elastase-1 (mg/g of stool) 7 (10±2) 10 (57±19)
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Background: Distal intestinal obstruction syndrome (DIOS) is deﬁned as partial
or complete bowel obstruction due to abnormally viscid mucofaecal material in the
terminal ileum and caecum in individuals with cystic ﬁbrosis (CF). The syndrome
encompasses a spectrum from acute obstruction to chronic pain, bloating and
bowel dysfunction. The long-term management of the most severe cases of DIOS
remains unsatisfactory. The prokinetic cisapride was shown to be effective but has
subsequently been withdrawn. Tegaserod is a 5-HT4 partial agonist which has been
shown to accelerate transit in the gastrointestinal tract and might therefore be useful
in this setting.
Methods: The Royal Brompton Hospital provides specialist CF care. A series of
patients, including cases with both acute obstruction and chronic symptoms, was
given a therapeutic trial of tegaserod. After three months of treatment, patients were
reviewed, using a visual-analogue scale to assess the subjective global relief.
Results: 10 patients received tegaserod 2mg twice daily. The age of onset of DIOS
could be established in 7 with a mean of 22.0 years (range 14−33). The mean age at
tegaserod treatment was 34.2 years (range 24−52). 8 cases had required admission
at some point for acute obstructive episodes. Subjective global relief of symptoms
at 3 months was scored at a mean of 49% (0−80%). 9 patients reported some
improvement, 1 no change and none reported deterioration. Patients consistently
reported improvements in pain, bloating and an increase in stool frequency.
Discussion: This uncontrolled case series presents the ﬁrst evidence that tegaserod
could be a useful therapy for DIOS. We feel that a randomised controlled trial of
tegaserod in DIOS is justiﬁed.
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Despite of pancreatic substitution some CF patients fail to achieve a good nutritional
status. In the stool of CF cases older than 4 years of age we proved increased concen-
tration of A1AT compared to the control group, indicating increased permeability
of the bowel wall. In order to learn if this feature is of inﬂammatory origin, we
examined lactoferrin concentration in stool by ELISA (IBD-SCAN; TechLab). Stool
concentration of lactoferrin was examined in 50 CF patients at the age 0.01−26.7
years (median 8.7). Assessment of lactoferrin was supplemented by the examination
of A1AT concentration and polymorphonuclear (PMN) Elastase activity (using spec-
trophotometry with substrate Glt.Ala.Ala.Pro.Val.pNA). In all cases concentration
of Elastase-1 (ELISA Elastase-1; Bioserv Diagnostic, Germany), clinical status,
nutrition, lung function, CRP and therapy were assessed. Median of lactoferrin
concentration in the stool of CF patients was 5.7 (2.8–130mg/ml). In 22/50 patients
it was above the population norm (>7.24mg/ml), comparable to that of patients
with ulcerative colitis in remission. As expected the concentration of lactoferrin
signiﬁcantly correlates with PMN Elastase activity (r = 0.44; p< 0.01). Increased
lactoferrin is more frequently associated with lower concentration of Elastase-1
(p = 0.05) and the presence of Class I−III CFTR gene genotypes. However, no
correlation was found with CRP, A1AT, nutritional status, pancreatic substitution,
abdominal pain, lung function, bacterial infection and/or therapy. In nearly half of
examined cases there was lactoferrin-based evidence of intestinal inﬂammation, but
surprisingly no correlation with nutritional status was observed. This issue needs
further study.
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In cystic ﬁbrosis (CF), the genotype is known to inﬂuence the fatty acid (FA)
composition. Diabetes mellitus and liver disease can inﬂuence FA status. Until
now, there are no data on the inﬂuence of CF related diabetes mellitus and CF
related liver disease (CFRLD) on the FA status of CF patients. The aim of this
study was to evaluate whether the presence of CFRLD inﬂuences the FA status.
Method: A fasting blood sample for determination of serum vitamin E and phos-
pholipid FA composition was withdrawn in 79 CF patients, with stable pulmonary
disease, under regular control in our CF centre. Patients with CFRLD (n = 13) were
compared to CF patients with the same severe genotype (n = 66).
Results: The CF patients with CFRLD, have a more pronounced decrease in DHA
(22:6 n-3) and an increase of docosatetraenoic acid (22:4 n-6) compared to the
CF patients of the same genotype. There were no signiﬁcant differences in the
precursors of these FAs.
Conclusion: DHA concentration in patients with CFRLD is more profoundly
decreased than in their genotype controls. The presence of CFRLD should be taken
into account in future FA studies in CF patients.
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